DE602007003703D1 - Gegen amyloid-beta peptid gerichtete antikörper - Google Patents

Gegen amyloid-beta peptid gerichtete antikörper

Info

Publication number: DE602007003703D1
Authority: DE; Germany
Prior art keywords: beta peptide; peptide antibodies; against amyloid; amyloid; antibodies
Prior art date: 2006-03-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

DE602007003703T

Other languages

English (en)

Inventor

Stephen Anthony Burbidge

Jonathan Henry Ellis

Susannah K Ford

Volker Germaschewski

Umesh Kumar

Karen Louise Philpott

Peter Ernest Soden

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-30

Filing date

2007-03-27

Publication date

2010-01-21

2007-03-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-01-21 Publication of DE602007003703D1 publication Critical patent/DE602007003703D1/de

Status Active legal-status Critical Current

2027-03-28 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DE602007003703T 2006-03-30 2007-03-27 Gegen amyloid-beta peptid gerichtete antikörper Active DE602007003703D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US78758806P	2006-03-30	2006-03-30
PCT/EP2007/052928 WO2007113172A2 (en)	2006-03-30	2007-03-27	Antibodies against amyloid-beta peptide

Publications (1)

Publication Number	Publication Date
DE602007003703D1 true DE602007003703D1 (de)	2010-01-21

Family

ID=38284050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE602007003703T Active DE602007003703D1 (de)	2006-03-30	2007-03-27	Gegen amyloid-beta peptid gerichtete antikörper

Country Status (32)

Country	Link
US (3)	US8227576B2 (de)
EP (2)	EP1996621B1 (de)
JP (1)	JP5103466B2 (de)
KR (2)	KR20120093400A (de)
CN (2)	CN101415729B (de)
AR (1)	AR060332A1 (de)
AT (1)	ATE451392T1 (de)
AU (1)	AU2007233831B2 (de)
BR (1)	BRPI0709246A2 (de)
CA (1)	CA2647808C (de)
CR (1)	CR10347A (de)
CY (1)	CY1109877T1 (de)
DE (1)	DE602007003703D1 (de)
DK (2)	DK1996621T3 (de)
EA (1)	EA015654B9 (de)
ES (2)	ES2338179T3 (de)
HR (2)	HRP20100115T1 (de)
IL (1)	IL193695A (de)
JO (1)	JO2576B1 (de)
MA (1)	MA30337B1 (de)
MX (1)	MX2008012483A (de)
MY (1)	MY149630A (de)
NO (1)	NO20083793L (de)
NZ (1)	NZ571038A (de)
PE (1)	PE20080181A1 (de)
PL (2)	PL1996621T3 (de)
PT (2)	PT1996621E (de)
SI (2)	SI1996621T1 (de)
TW (1)	TWI385179B (de)
UA (1)	UA94734C2 (de)
WO (1)	WO2007113172A2 (de)
ZA (1)	ZA200807911B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO2004060403A2 (en)	2003-01-06	2004-07-22	Angiochem Inc.	Aprotinin and anglos as carriers across the blood-brain barrier
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
AU2006208226A1 (en)	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
KR101439828B1 (ko)	2005-11-30	2014-09-17	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
JP5475994B2 (ja)	2005-11-30	2014-04-16	アッヴィ・インコーポレイテッド	抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
AR062065A1 (es)	2006-07-14	2008-10-15	Ac Immune Sa	Anticuerpo humanizado
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US7931899B2 (en)	2007-05-14	2011-04-26	Medtronic, Inc	Humanized anti-amyloid beta antibodies
US8323654B2 (en)	2007-05-14	2012-12-04	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
SI2182983T1 (sl) *	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
AU2008290607B2 (en) *	2007-08-20	2013-11-14	Glaxo Group Limited	Production method
GB0718737D0 (en) *	2007-09-25	2007-11-07	Glaxo Group Ltd	Antibodies
EP2205631B1 (de) *	2007-10-05	2016-11-23	Genentech, Inc.	Methoden und zusammensetzungen zur diagnose und behandlung von amyloidose
PT2238166E (pt)	2007-10-05	2014-02-11	Genentech Inc	Utilização do anticorpo anti-amilóide beta em doenças oculares
EP2592147A1 (de)	2007-10-12	2013-05-15	F. Hoffmann-La Roche AG	Proteinexpression von mehreren Nukleinsäuren
JO3076B1 (ar) *	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2222700A2 (de) *	2007-11-27	2010-09-01	Medtronic, Inc.	Humanisierte anti-amyloid-beta-antikörper
AR069610A1 (es) *	2007-12-11	2010-02-03	Glaxo Group Ltd	Proteinas de union a antigenos que se unen al peptido beta-amiloide
AU2008343855B2 (en) *	2007-12-21	2013-08-15	Amgen Inc.	Anti-amyloid antibodies and uses thereof
UY31810A (es)	2008-05-06	2009-12-14	Glaxo Group Ltd	Encapsulación de agentes biológicamente activos
AU2009304560A1 (en)	2008-10-15	2010-04-22	Angiochem Inc.	Conjugates of GLP-1 agonists and uses thereof
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US9914754B2 (en)	2008-12-05	2018-03-13	Angiochem Inc.	Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2010239069B2 (en)	2009-04-20	2015-05-14	Angiochem Inc	Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
JP5932642B2 (ja) *	2009-07-02	2016-06-08	アンジオケムインコーポレーテッド	多量体ペプチドコンジュゲートおよびその使用
CN102695546B (zh)	2009-09-11	2014-09-10	前体生物药物股份公司	作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
EP2308897A1 (de) *	2009-10-09	2011-04-13	Pierre Fabre Medicament	Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
CA2788275A1 (en)	2010-03-03	2011-09-09	Boehringer Ingelheim International Gmbh	Biparatopic abeta binding polypeptides
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
WO2011149461A1 (en) *	2010-05-27	2011-12-01	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
MX341369B (es)	2010-07-30	2016-08-17	Genentech Inc *	Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
EP3533803B1 (de)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antikörper
EA034333B1 (ru)	2010-11-30	2020-01-29	Дженентек, Инк.	Варианты антитела для переноса соединения через гематоэнцефалический барьер
CA2826286C (en)	2011-01-31	2021-09-21	Intellect Neurosciences Inc.	Treatment of tauopathies
AU2012245260B2 (en)	2011-04-22	2016-09-08	Aptevo Research And Development Llc	Prostate-specific membrane antigen binding proteins and related compositions and methods
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
EP3594239B1 (de)	2012-05-21	2024-10-30	F. Hoffmann-La Roche AG	Verfahren für verbesserte sicherheit des blut-hirn-schranken-transports
RU2509155C1 (ru) *	2012-10-25	2014-03-10	Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук	Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
EP3011343A2 (de)	2013-06-19	2016-04-27	Glaxosmithkline Intellectual Property (No. 2) Limited	Test für komplementfaktor-i (cfi)-bioaktivität
CN104558172A (zh) *	2015-01-04	2015-04-29	东南大学	一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
EP3307326B9 (de)	2015-06-15	2021-02-24	Angiochem Inc.	Verfahren zur behandlung von leptomeningealer karzinomatose
UA126278C2 (uk)	2015-09-21	2022-09-14	Аптево Рісьорч Енд Девелопмент Ллс	Поліпептиди, які зв'язують cd3
WO2017072090A1 (en) *	2015-10-27	2017-05-04	Glaxosmithkline Intellectual Property Development Limited	Combination therapy
JP2020526191A (ja)	2017-06-29	2020-08-31	ザトラスティーズオブコロンビアユニバーシティインザシティオブニューヨークＴｈｅＴｒｕｓｔｅｅｓＯｆＣｏｌｕｍｂｉａＵｎｉｖｅｒｓｉｔｙＩｎＴｈｅＣｉｔｙＯｆＮｅｗＹｏｒｋ	アミロイド沈着疾患を治療するためのキメラ抗体
US11382974B2 (en)	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
US12325741B2 (en) *	2018-07-17	2025-06-10	Jiangsu Hengrui Medicine Co., Ltd.	Anti-Aβ antibodies and antigen-binding fragments thereof
CA3135170A1 (en)	2019-04-05	2020-10-08	Tauc3 Biologics Limited	Anti-tauc3 antibodies and uses thereof
JP2023535024A (ja)	2020-07-23	2023-08-15	オタープロシーナリミテッド	抗ａベータ抗体
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (en)	2021-05-24	2022-12-01	Eli Lilly And Company	Anti-amyloid beta antibodies and uses thereof
CN114591917B (zh) *	2022-05-07	2022-09-02	北京第一生物化学药业有限公司	产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
CN114591918B (zh) *	2022-05-07	2022-07-26	北京第一生物化学药业有限公司	产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) *	2022-09-08	2023-05-11	주식회사 알츠코리아	아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) *	2024-08-19	2024-11-22	成都迈科康生物科技有限公司	一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5811517A (en) *	1992-01-27	1998-09-22	Icos Corporation	ICAM-related protein variants
EP2006303A1 (de) *	1997-04-09	2008-12-24	Intellect Neurosciences, Inc.	Beta-Amyloid-Enden-spezifische rekombinante Antikörper, DNS-Codierung und Verwendungsverfahren
US7179892B2 (en) *	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
JP2002530122A (ja) *	1998-11-25	2002-09-17	サイオスインコーポレイテッド	アミロイド関連疾患の予防及び治療
DE1257584T1 (de) *	2000-02-24	2003-05-28	Lilly Co Eli	Humanisierte antikörper, die amyloid beta peptid demarkieren
AU2002239766B9 (en) *	2000-11-03	2007-04-05	The J. David Gladstone Institutes	Methods of treating disorders related to apoE
WO2004029629A1 (en) *	2002-09-27	2004-04-08	Janssen Pharmaceutica N.V.	N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) *	2002-10-08	2004-04-09	Pro Cord Spa	Schienale di sedia.
PL377769A1 (pl) *	2002-10-09	2006-02-20	Rinat Neuroscience Corp.	Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje

2007
- 2007-03-27 EA EA200801842A patent/EA015654B9/ru not_active IP Right Cessation
- 2007-03-27 UA UAA200810923A patent/UA94734C2/ru unknown
- 2007-03-27 CN CN2007800124360A patent/CN101415729B/zh not_active Expired - Fee Related
- 2007-03-27 DK DK07727401.7T patent/DK1996621T3/da active
- 2007-03-27 JP JP2009502072A patent/JP5103466B2/ja not_active Expired - Fee Related
- 2007-03-27 EP EP07727401A patent/EP1996621B1/de not_active Not-in-force
- 2007-03-27 PT PT07727401T patent/PT1996621E/pt unknown
- 2007-03-27 AT AT07727401T patent/ATE451392T1/de active
- 2007-03-27 ES ES07727401T patent/ES2338179T3/es active Active
- 2007-03-27 CA CA2647808A patent/CA2647808C/en not_active Expired - Fee Related
- 2007-03-27 DE DE602007003703T patent/DE602007003703D1/de active Active
- 2007-03-27 PL PL07727401T patent/PL1996621T3/pl unknown
- 2007-03-27 ES ES09178407.4T patent/ES2484967T3/es active Active
- 2007-03-27 KR KR1020127016745A patent/KR20120093400A/ko not_active Withdrawn
- 2007-03-27 PT PT91784074T patent/PT2177536E/pt unknown
- 2007-03-27 EP EP09178407.4A patent/EP2177536B1/de not_active Not-in-force
- 2007-03-27 NZ NZ571038A patent/NZ571038A/en not_active IP Right Cessation
- 2007-03-27 AU AU2007233831A patent/AU2007233831B2/en not_active Ceased
- 2007-03-27 MX MX2008012483A patent/MX2008012483A/es active IP Right Grant
- 2007-03-27 BR BRPI0709246-6A patent/BRPI0709246A2/pt not_active IP Right Cessation
- 2007-03-27 WO PCT/EP2007/052928 patent/WO2007113172A2/en not_active Ceased
- 2007-03-27 CN CN201310338011.6A patent/CN103539857A/zh active Pending
- 2007-03-27 KR KR1020087026640A patent/KR101263294B1/ko not_active Expired - Fee Related
- 2007-03-27 SI SI200730173T patent/SI1996621T1/sl unknown
- 2007-03-27 US US12/294,438 patent/US8227576B2/en not_active Expired - Fee Related
- 2007-03-27 DK DK09178407.4T patent/DK2177536T3/da active
- 2007-03-27 HR HR20100115T patent/HRP20100115T1/hr unknown
- 2007-03-27 PL PL09178407T patent/PL2177536T3/pl unknown
- 2007-03-27 SI SI200731503T patent/SI2177536T1/sl unknown
- 2007-03-28 PE PE2007000354A patent/PE20080181A1/es not_active Application Discontinuation
- 2007-03-28 JO JO200788A patent/JO2576B1/en active
- 2007-03-28 AR ARP070101295A patent/AR060332A1/es not_active Application Discontinuation
- 2007-03-28 TW TW096110663A patent/TWI385179B/zh not_active IP Right Cessation
2008
- 2008-08-26 IL IL193695A patent/IL193695A/en not_active IP Right Cessation
- 2008-09-03 NO NO20083793A patent/NO20083793L/no not_active Application Discontinuation
- 2008-09-15 ZA ZA200807911A patent/ZA200807911B/xx unknown
- 2008-09-26 MY MYPI20083843A patent/MY149630A/en unknown
- 2008-10-07 CR CR10347A patent/CR10347A/es unknown
- 2008-10-15 MA MA31293A patent/MA30337B1/fr unknown
2010
- 2010-03-01 CY CY20101100198T patent/CY1109877T1/el unknown
2012
- 2012-06-08 US US13/491,810 patent/US9193784B2/en not_active Expired - Fee Related
2014
- 2014-06-30 HR HRP20140618TT patent/HRP20140618T1/hr unknown
2015
- 2015-10-13 US US14/881,428 patent/US20160024197A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN103539857A (zh)	2014-01-29
AU2007233831B2 (en)	2013-02-14
NO20083793L (no)	2008-10-13
PT1996621E (pt)	2010-03-08
TW200815466A (en)	2008-04-01
MX2008012483A (es)	2008-10-10
CN101415729A (zh)	2009-04-22
KR20080113273A (ko)	2008-12-29
SI1996621T1 (sl)	2010-04-30
HRP20140618T1 (hr)	2014-08-15
EP2177536A1 (de)	2010-04-21
CR10347A (es)	2008-10-29
US20160024197A1 (en)	2016-01-28
ES2338179T3 (es)	2010-05-04
IL193695A0 (en)	2011-08-01
JO2576B1 (en)	2011-02-27
HK1122311A1 (en)	2009-05-15
HRP20100115T1 (hr)	2010-04-30
MA30337B1 (fr)	2009-04-01
DK1996621T3 (da)	2010-04-19
CA2647808C (en)	2015-11-17
PL1996621T3 (pl)	2010-05-31
PL2177536T3 (pl)	2014-11-28
HK1138015A1 (en)	2010-08-13
US20110142824A1 (en)	2011-06-16
US8227576B2 (en)	2012-07-24
EP1996621A2 (de)	2008-12-03
US20140050719A1 (en)	2014-02-20
JP5103466B2 (ja)	2012-12-19
AU2007233831A1 (en)	2007-10-11
TWI385179B (zh)	2013-02-11
PT2177536E (pt)	2014-08-22
CY1109877T1 (el)	2014-09-10
US9193784B2 (en)	2015-11-24
UA94734C2 (ru)	2011-06-10
CN101415729B (zh)	2013-09-04
DK2177536T3 (da)	2014-07-14
EA200801842A1 (ru)	2009-02-27
ES2484967T3 (es)	2014-08-12
MY149630A (en)	2013-09-13
IL193695A (en)	2012-05-31
EA015654B9 (ru)	2012-01-30
SI2177536T1 (sl)	2014-09-30
NZ571038A (en)	2011-03-31
PE20080181A1 (es)	2008-03-16
AR060332A1 (es)	2008-06-11
ATE451392T1 (de)	2009-12-15
JP2009531380A (ja)	2009-09-03
KR101263294B1 (ko)	2013-06-04
EP2177536B1 (de)	2014-06-04
WO2007113172A2 (en)	2007-10-11
WO2007113172A3 (en)	2007-11-29
CA2647808A1 (en)	2007-10-11
KR20120093400A (ko)	2012-08-22
EP1996621B1 (de)	2009-12-09
BRPI0709246A2 (pt)	2011-07-12
EA015654B1 (ru)	2011-10-31
ZA200807911B (en)	2009-11-25

Publication	Publication Date	Title
DE602007003703D1 (de)	2010-01-21	Gegen amyloid-beta peptid gerichtete antikörper
EP2093287A4 (de)	2010-04-21	Igg bindendes peptid
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
BRPI0818288A2 (pt)	2015-04-14	Proteínas conjugadas e peptídeos.
EP1961761A4 (de)	2009-01-21	Neue peptidverbindung
DK2046826T3 (da)	2011-10-24	Exendin-fusionsproteiner
EP2215246A4 (de)	2011-08-10	Proteingerüste
EP2118122A4 (de)	2012-12-12	Neuartige antimikrobielle peptide
ATE501174T1 (de)	2011-03-15	Antikörper gegen madcam
BRPI0814587A2 (pt)	2015-01-20	Peptídeos antibióticos
BRPI0907363A2 (pt)	2015-08-18	Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
BRPI0911743A2 (pt)	2015-07-07	"peptídeo"
EP2006377A4 (de)	2009-12-09	Neue tumorantigenpeptide
DK2035447T3 (da)	2017-11-06	Polypeptid
DK2035451T3 (da)	2010-06-07	Insulinoptrop peptidsyntese
DE602005015131D1 (de)	2009-08-06	Interleukin-15-antagonistisches peptid
EP2010561A4 (de)	2010-03-24	Antimikrobielle peptide
BRPI0814127A2 (pt)	2015-02-03	Polipeptídeos imunegênicos e anticorpos monoclonais
EP2101804A4 (de)	2010-06-16	Proangiogene peptide
ATE547425T1 (de)	2012-03-15	Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)
EP2015785A4 (de)	2009-07-15	Agrm2-antigen
DK1968623T3 (da)	2012-06-04	Bacteriocin-inducer-peptider
EP2370100A4 (de)	2013-05-22	Peptidhilfsstoffe
DK2081952T3 (da)	2014-04-28	Peptider
FI20075483A0 (fi)	2007-06-25	Uusi peptidi

Legal Events

Date	Code	Title	Description
2010-12-30	8364	No opposition during term of opposition